A BILL 
To amend title XVIII of the Social Security Act to ensure 
prompt coverage of breakthrough devices under the Medi-
care program, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Ensuring Patient Ac-
4
cess to Critical Breakthrough Products Act of 2019’’. 
5
05:09 Dec 13, 2019
H5333
2 
•HR 5333 IH
SEC. 2. COVERAGE AND PAYMENT FOR BREAKTHROUGH 
1
DEVICES UNDER THE MEDICARE PROGRAM. 
2
(a) IN GENERAL.—Part E of title XVIII of the Social 
3
Security Act (42 U.S.C. 1395x et seq.) is amended by add-
4
ing at the end the following new section: 
5
‘‘SEC. 1899C. COVERAGE OF BREAKTHROUGH DEVICES. 
6
‘‘(a) BREAKTHROUGH DEVICES.— 
7
‘‘(1) IN GENERAL.—For purposes of this sec-
8
tion, the term ‘breakthrough device’ means a med-
9
ical device that is a device (as defined in section 201 
10
of the Federal Food, Drug, and Cosmetic Act) and 
11
that is— 
12
‘‘(A) provided with review priority by the 
13
Secretary under subsection (d)(5) of section 
14
515 of such Act; and 
15
‘‘(B) approved or cleared pursuant to sec-
16
tion 510(k), 513(f), or 515 of such Act for use 
17
in treating an indication on or after July 1, 
18
2019. 
19
Such term also includes a breakthrough device that 
20
is a specified breakthrough device (as defined in sub-
21
section (e)(1)(B)) approved or cleared pursuant to 
22
section 510(k), 513(f), or 515 of such Act for use 
23
in treating an indication on or after December 1, 
24
2018. 
25
05:09 Dec 13, 2019
H5333
3 
•HR 5333 IH
‘‘(2) LIMITATION ON NUMBER OF 510(K) DE-
1
VICES.—With respect to a 5-year period, in no case 
2
may more than five medical devices described in 
3
paragraph (1) that are classified under section 
4
510(k) of the Federal Food, Drug, and Cosmetic 
5
Act be covered and paid for under this title by rea-
6
son of this section during each such 5-year period. 
7
‘‘(b) COVERAGE.— 
8
‘‘(1) TRANSITIONAL COVERAGE.— 
9
‘‘(A) IN
GENERAL.—During the transi-
10
tional coverage period (as defined in subpara-
11
graph (B)) a breakthrough device shall be— 
12
‘‘(i) deemed to be reasonable and nec-
13
essary 
for 
purposes 
of 
section 
14
1862(a)(1)(A); 
15
‘‘(ii) deemed to be approved for an ad-
16
ditional 
payment 
under 
section 
17
1886(d)(5)(K) (other than with respect to 
18
the cost criterion under clause (ii)(I) of 
19
such section); 
20
‘‘(iii) deemed to be approved for pass- 
21
through payment under section 1833(t)(6) 
22
and section 1833(i) (other than with re-
23
spect to the cost criterion under section 
24
1833(t)(6)(A)(iv)); and 
25
05:09 Dec 13, 2019
H5333
4 
•HR 5333 IH
‘‘(iv) insofar as such breakthrough de-
1
vice may be furnished in a setting for 
2
which payment is made under an applica-
3
ble payment system described in subpara-
4
graphs (D) through (I) of subsection 
5
(c)(4), deemed eligible for an additional 
6
payment or payment adjustment, as the 
7
case may be, pursuant to subsection (d)(3) 
8
when furnished in a setting for which pay-
9
ment is made under such an applicable 
10
payment system during such transitional 
11
coverage period. 
12
‘‘(B) TRANSITIONAL
COVERAGE
PERIOD 
13
DEFINED.—As used in this section, the term 
14
‘transitional coverage period’ means, with re-
15
spect to a breakthrough device, the period 
16
that— 
17
‘‘(i) begins on the date of the approval 
18
under section 515 of the Federal Food, 
19
Drug, and Cosmetic Act or of the clear-
20
ance under section 510(k) of such Act, as 
21
applicable, of such device by the Secretary 
22
for the indication described in subsection 
23
(a)(1); and 
24
05:09 Dec 13, 2019
H5333
5 
•HR 5333 IH
‘‘(ii) ends on the last day of the 3- 
1
year period that begins on the date that 
2
the Secretary, pursuant to subsection 
3
(c)(2), updates the relevant applicable pay-
4
ment system (as defined in subsection 
5
(c)(4)) to recognize the unique temporary 
6
or permanent code or codes assigned under 
7
subsection (c)(1) to such breakthrough de-
8
vice, except as provided in subsections 
9
(d)(1)(B) and (d)(2)(B). 
10
‘‘(C) DATA USED TO MEET THE NTAP AND 
11
PASS-THROUGH
COST
CRITERIA.—In 
deter-
12
mining whether a breakthrough device qualifies 
13
for an additional payment under section 
14
1886(d)(5)(K) or for pass-through payment 
15
under section 1833(t)(6) or section 1833(i), the 
16
Secretary shall use the most recently available 
17
data and information on the costs of such 
18
breakthrough device, which may include list 
19
prices and invoice prices charged for such 
20
breakthrough device. 
21
‘‘(2) PROCESS FOR REGULAR COVERAGE.—For 
22
purposes of the application of section 1862(a)(1)(A) 
23
to a breakthrough device furnished after the transi-
24
tional coverage period (as defined in paragraph 
25
05:09 Dec 13, 2019
H5333
6 
•HR 5333 IH
(1)(B)) for such device, the Secretary shall establish 
1
a process for the coverage of such breakthrough de-
2
vices under this title after such period as follows: 
3
‘‘(A) IDENTIFICATION OF ADDITIONAL EVI-
4
DENCE.— 
5
‘‘(i) IN GENERAL.—With respect to a 
6
breakthrough device, not later than 1 year 
7
after the date of the approval of such de-
8
vice under section 515 of the Federal 
9
Food, Drug, and Cosmetic Act or of the 
10
clearance of such device under section 
11
510(k) of such Act, as applicable, the Sec-
12
retary shall identify whether any additional 
13
data or evidence is required with respect to 
14
any indications for such device for pur-
15
poses of the application of such section 
16
1862(a)(1)(A) to such device for such indi-
17
cations. 
18
‘‘(ii) NON-DUPLICATION OF DATA RE-
19
QUESTS.—In carrying out clause (i) with 
20
respect to a breakthrough device, the Sec-
21
retary shall ensure that data or evidence 
22
identified— 
23
‘‘(I) does not duplicate data re-
24
quired to be collected by the Food and 
25
05:09 Dec 13, 2019
H5333
7 
•HR 5333 IH
Drug Administration with respect to 
1
such breakthrough device; 
2
‘‘(II) minimizes the administra-
3
tive burdens of data collection and re-
4
porting on providers of services, sup-
5
pliers, and manufacturers of break-
6
through devices; and 
7
‘‘(III) is not otherwise unneces-
8
sary or redundant. 
9
‘‘(B) PROPOSAL
FOR
COVERAGE
AFTER 
10
THE
TRANSITIONAL
COVERAGE
PERIOD.—Not 
11
later than 2 years after the date of the approval 
12
or clearance of a breakthrough device by the 
13
Food and Drug Administration, the Secretary 
14
shall develop a proposal for coverage under this 
15
title of such breakthrough device for such indi-
16
cations as the Secretary determines to be ap-
17
propriate, based on the data and evidence col-
18
lected under subparagraph (A), for such devices 
19
furnished after the transitional coverage period 
20
under paragraph (1) for such device. If the Sec-
21
retary does not, on a date that is before the end 
22
of such two-year period, take action to modify 
23
the indications for which coverage of a break-
24
through device may be provided under this title 
25
05:09 Dec 13, 2019
H5333
8 
•HR 5333 IH
after such period, for purposes of section 
1
1862(a)(1)(A) coverage under this title of such 
2
breakthrough device shall be made for all indi-
3
cations for which such device is approved under 
4
section 515 of the Federal Food, Drug, and 
5
Cosmetic Act or cleared under section 510(k) of 
6
such Act. 
7
‘‘(3) RULES
OF
CONSTRUCTION.—Nothing in 
8
this section shall be construed to— 
9
‘‘(A) affect the ability of the manufacturer 
10
of a breakthrough device to seek approval for 
11
pass-through payment status under section 
12
1833(t)(6) or to seek approval for an additional 
13
payment under section 1886(d)(5)(K) insofar 
14
as such breakthrough device does not qualify 
15
for transitional coverage under paragraph (1); 
16
or 
17
‘‘(B) affect the application and approval 
18
process for pass-through payment status under 
19
section 1833(t)(6) or for an additional payment 
20
under section 1886(d)(5)(K) in the case of a 
21
medical device that is not approved by the Food 
22
and Drug Administration as a breakthrough de-
23
vice. 
24
‘‘(c) CODING.— 
25
05:09 Dec 13, 2019
H5333
9 
•HR 5333 IH
‘‘(1) PROMPT
ASSIGNMENT.—Not later than 
1
three months after the date of approval or clearance 
2
of a breakthrough device by the Food and Drug Ad-
3
ministration, subject to subparagraph (B), the Sec-
4
retary shall assign a unique temporary or permanent 
5
code or codes for purposes of coverage and payment 
6
for such breakthrough device under the applicable 
7
payment systems (described in paragraph (4)). 
8
‘‘(2) UPDATES.— 
9
‘‘(A) IPPS.—The Secretary shall provide 
10
for semiannual updates under the applicable 
11
payment system described in paragraph (4)(A) 
12
(relating to the inpatient hospital prospective 
13
payment system) to recognize the code or codes 
14
assigned under paragraph (1). 
15
‘‘(B) OPPS.—The Secretary shall provide 
16
for quarterly updates under the applicable pay-
17
ment system described in paragraph (4)(B) (re-
18
lating to the outpatient hospital prospective 
19
payment system) to recognize the code or codes 
20
assigned under paragraph (1). 
21
‘‘(C) OTHER
PAYMENT
SYSTEMS.—The 
22
Secretary shall provide for semiannual or quar-
23
terly updates, as the case may be, under the ap-
24
plicable payment systems described in subpara-
25
05:09 Dec 13, 2019
H5333
10 
•HR 5333 IH
graphs (C) through (L) of paragraph (4) to rec-
1
ognize the code or codes assigned under para-
2
graph (1). 
3
‘‘(3) TRANSPARENCY.—The process for the as-
4
signment of a code or codes under this subsection 
5
shall provide for public notice and a meaningful op-
6
portunity for public comment from affected parties. 
7
‘‘(4) APPLICABLE
PAYMENT
SYSTEMS
DE-
8
SCRIBED.—For purposes of this subsection, the term 
9
‘applicable payment systems’ means— 
10
‘‘(A) with respect to inpatient hospital 
11
services, the prospective payment system for in-
12
patient hospital services established under sec-
13
tion 1886(d); 
14
‘‘(B) with respect to outpatient hospital 
15
services, the prospective payment system for 
16
covered OPD services established under section 
17
1833(t); 
18
‘‘(C) with respect to ambulatory surgical 
19
center services, the fee schedule for such serv-
20
ices established under 1833(i); 
21
‘‘(D) with respect to physicians’ services, 
22
the physician fee schedules established under 
23
section 1848; 
24
05:09 Dec 13, 2019
H5333
11 
•HR 5333 IH
‘‘(E) with respect to covered items of dura-
1
ble medical equipment, the applicable fee sched-
2
ules established under section 1834; 
3
‘‘(F) with respect to diagnostic laboratory 
4
tests, the payment amounts under section 
5
1834A and the fee schedules establish under 
6
section 1848, as the case may be; 
7
‘‘(G) with respect to inpatient hospital 
8
services furnished by rehabilitation facilities, 
9
the prospective payment system established 
10
under section 1886(j); 
11
‘‘(H) with respect to inpatient hospital 
12
services furnished by long-term care hospitals, 
13
the prospective payment system under section 
14
1886(m); 
15
‘‘(I) with respect to inpatient hospital serv-
16
ices furnished by psychiatric hospitals and psy-
17
chiatric units, the prospective payment system 
18
under section 1886(s); 
19
‘‘(J) with respect to home health services, 
20
the prospective payment system under section 
21
1895; and 
22
‘‘(K) with respect to items and services, or 
23
a provider of services or supplier, not described 
24
in subparagraphs (A) through (I), the payment 
25
05:09 Dec 13, 2019
H5333
12 
•HR 5333 IH
system established under this title for such 
1
items and services when furnished by such pro-
2
vider of services or supplier. 
3
‘‘(d) PAYMENT.— 
4
‘‘(1) INPATIENT HOSPITAL PROSPECTIVE PAY-
5
MENT SYSTEM: DEEMED ELIGIBILITY FOR BREAK-
6
THROUGH
PAYMENT.—The Secretary shall deem 
7
each breakthrough device as approved for an addi-
8
tional payment under section 1886(d)(5)(K) for the 
9
3-year period that begins— 
10
‘‘(A) except as provided in subparagraph 
11
(B), on the date that the Secretary, pursuant to 
12
subsection (c)(2)(A), updates the payment sys-
13
tem under section 1886(d) to recognize the 
14
unique temporary or permanent code or codes 
15
assigned under subsection (c)(1) to such break-
16
through device; or 
17
‘‘(B) in the case of a device that has not 
18
received approval or clearance as a break-
19
through device by the Food and Drug Adminis-
20
tration before such payment system is updated 
21
under subsection (c)(2)(A) to recognize the 
22
unique temporary or permanent code or codes 
23
assigned under subsection (c)(1) to such device, 
24
on the date of such approval or clearance. 
25
05:09 Dec 13, 2019
H5333
13 
•HR 5333 IH
Nothing in this paragraph shall be construed to af-
1
fect the authority of the Secretary to use claims 
2
data to establish new diagnosis or procedure codes 
3
for breakthrough devices or to identify appropriate 
4
diagnosis-related groups for the assignment of 
5
breakthrough devices under annual rulemaking to 
6
carry out section 1886(d)(5)(K). 
7
‘‘(2) OUTPATIENT PROSPECTIVE PAYMENT SYS-
8
TEM: DEEMED
ELIGIBILITY
FOR
PASS-THROUGH 
9
PAYMENT.—The Secretary shall deem each break-
10
through device as approved for pass-through pay-
11
ment under section 1833(t)(6) (including for pur-
12
poses of section 1833(i)(2)(D)) during the 3-year pe-
13
riod that begins— 
14
‘‘(A) except as provided in subparagraph 
15
(B), on the date that the Secretary, pursuant to 
16
subsection (c)(2)(B), updates the payment sys-
17
tem under section 1833(t) to recognize the 
18
unique temporary or permanent code or codes 
19
assigned under subsection (c)(1) to such break-
20
through device; or 
21
‘‘(B) in the case of a device that has not 
22
received approval or clearance as a break-
23
through device by the Food and Drug Adminis-
24
tration before such payment system is updated 
25
05:09 Dec 13, 2019
H5333
14 
•HR 5333 IH
under subsection (c)(2)(B) to recognize the 
1
unique temporary or permanent code or codes 
2
assigned under subsection (c)(1) to such device, 
3
on the date of such approval or clearance. 
4
Nothing in this paragraph shall be construed to af-
5
fect the authority of the Secretary to use claims 
6
data to establish new ambulatory payment classifica-
7
tion groups for breakthrough devices or to revise 
8
such groups to take into account breakthrough de-
9
vices under annual rulemaking to carry out section 
10
1833(t). 
11
‘‘(3) OTHER PAYMENT SYSTEMS.— 
12
‘‘(A) IN GENERAL.—In the case of break-
13
through device that is furnished and for which 
14
payment may be made under the payment sys-
15
tem established under section 1834, 1834A, 
16
1848, 1886(j), 1886(m), 1886(s), or 1895 or 
17
any other provision of this title (other than sec-
18
tions 1833(i), 1833(t), and 1886(d)), the Sec-
19
retary shall provide for an additional payment 
20
for such breakthrough device under such appli-
21
cable payment system or an adjustment to such 
22
applicable payment system, as the case may be. 
23
The payment basis for such additional payment 
24
or adjustment, as the case may be, shall equal 
25
05:09 Dec 13, 2019
H5333
15 
•HR 5333 IH
an amount that the Secretary determines covers 
1
the costs of such breakthrough device. 
2
‘‘(B) COST INFORMATION.—In determining 
3
the costs of a breakthrough device for purposes 
4
of determining an additional payment or pay-
5
ment adjustment under subparagraph (A), the 
6
Secretary shall use the most recently available 
7
data and information on the costs of such 
8
breakthrough device, which may include list 
9
prices and invoice prices charged for such 
10
breakthrough device. 
11
‘‘(C) RULE OF CONSTRUCTION.—Nothing 
12
in this paragraph shall be construed to affect 
13
the authority of the Secretary to use claims 
14
data to establish new or modify existing ambu-
15
latory payment classification groups, diagnosis- 
16
related groups, level II HCPCS codes or such 
17
other groups or codes as the Secretary may es-
18
tablish under the annual rulemaking authority 
19
under the provisions referred to in subpara-
20
graph (A). 
21
‘‘(D) CLINICAL DIAGNOSTIC LABORATORY 
22
TESTS.—An additional payment or payment ad-
23
justment under subparagraph (A) for a break-
24
through device under the applicable payment 
25
05:09 Dec 13, 2019
H5333
16 
•HR 5333 IH
system established in section 1834A may be in 
1
the form of an increase to the amount deter-
2
mined for the breakthrough device using cross- 
3
walking under section 1834A(c)(1)(A), an ex-
4
tension of the initial period of payment applica-
5
ble to advance diagnostic laboratory tests under 
6
section 1834A(d)(1)(A), and in such other form 
7
or manner as the Secretary determines reflects 
8
the costs for such breakthrough device under 
9
the relevant provisions of section 1834A. 
10
‘‘(4) PAYMENT FOR BREAKTHROUGH DEVICES 
11
AFTER
THE
TRANSITIONAL
COVERAGE
PERIOD.— 
12
Payment for a breakthrough device that is furnished 
13
after the conclusion of the transitional coverage pe-
14
riod under subsection (b)(1) for such device shall be 
15
made pursuant to the applicable payment system in-
16
volved, taking into account the additional evidence 
17
and data collected under subsection (b)(2). 
18
‘‘(e) SPECIAL RULES FOR CERTAIN BREAKTHROUGH 
19
DEVICES.— 
20
‘‘(1) COVERAGE OF SPECIFIED BREAKTHROUGH 
21
DEVICES.— 
22
‘‘(A) IN
GENERAL.—Subject to the suc-
23
ceeding provisions of this subsection and not-
24
withstanding any other provision of law, the 
25
05:09 Dec 13, 2019
H5333
17 
•HR 5333 IH
Secretary shall provide for coverage and pay-
1
ment pursuant to this section of a specified 
2
breakthrough device (as defined in subpara-
3
graph (B)). 
4
‘‘(B) SPECIFIED BREAKTHROUGH DEVICE 
5
DEFINED.—In this section, the term ‘specified 
6
breakthrough device’ means a breakthrough de-
7
vice with respect to which no Medicare benefit 
8
category exists. 
9
‘‘(2) PERIOD OF TRANSITIONAL COVERAGE.— 
10
‘‘(A) IN
GENERAL.—Subject to subpara-
11
graph (C), the provisions of subsection (b)(1) 
12
(relating to the transitional coverage period and 
13
payment for breakthrough devices, including the 
14
use of the most recently available data and in-
15
formation on costs) shall apply to a specified 
16
breakthrough device in the same manner as 
17
such provisions apply to a breakthrough device. 
18
The Secretary may use methodologies under ex-
19
isting payment systems established under this 
20
title, may provide for appropriate adjustments 
21
to such methodologies, or may establish a new 
22
payment methodology under this title, to pro-
23
vide for payment for a specified breakthrough 
24
device to ensure the payment basis for such 
25
05:09 Dec 13, 2019
H5333
18 
•HR 5333 IH
payment covers costs of the specified break-
1
through device are covered by such payment. 
2
‘‘(B) REPORT.— 
3
‘‘(i) IN
GENERAL.—With respect to 
4
each specified breakthrough device, the 
5
Secretary shall submit to Congress a re-
6
port on the coverage of and payment for 
7
such specified breakthrough device under 
8
this section that includes the following in-
9
formation: 
10
‘‘(I) The manner in which cov-
11
erage is provided and payment is 
12
made for the specified breakthrough 
13
device, including how such device was 
14
classified (such as an item of durable 
15
medical equipment or otherwise) and 
16
the payment methodology the Sec-
17
retary applied with respect to such de-
18
vice. 
19
‘‘(II) The impact of the avail-
20
ability of the specified breakthrough 
21
device to Medicare beneficiaries, in-
22
cluding impacts on the quality of pa-
23
tient care, patient outcomes, and pa-
24
tient experience. 
25
05:09 Dec 13, 2019
H5333
19 
•HR 5333 IH
‘‘(III) The impact of the avail-
1
ability of the specified breakthrough 
2
device to Medicare beneficiaries on 
3
program expenditures under this title. 
4
‘‘(IV) Such other information as 
5
the Secretary determines to be appro-
6
priate. 
7
‘‘(ii) DEADLINE.— 
8
‘‘(I) IN
GENERAL.—Except as 
9
provided in subclause (II), the Sec-
10
retary shall submit a report required 
11
under this subparagraph no later than 
12
the end of the transitional period of 
13
coverage and payment applicable to 
14
such specified breakthrough device. 
15
‘‘(II) EXTENSION TO GENERATE 
16
ADDITIONAL DATA.—If the Secretary 
17
determines that additional data or evi-
18
dence is required to complete a report 
19
required under this subparagraph 
20
with respect to a specified break-
21
through device, the deadline under 
22
this clause may be extended for an 
23
additional two years. 
24
05:09 Dec 13, 2019
H5333
20 
•HR 5333 IH
‘‘(C) ADDITIONAL
PERIOD
OF
TRANSI-
1
TIONAL
COVERAGE
TO
DEVELOP
ADDITIONAL 
2
DATA.—Insofar as the Secretary determines 
3
that additional data or evidence is required to 
4
complete a report required under subparagraph 
5
(B) with respect to a specified breakthrough de-
6
vice, the transitional coverage period of cov-
7
erage and payment for such device shall be ex-
8
tended by the lesser of— 
9
‘‘(i) two years; or 
10
‘‘(ii) the amount of additional time re-
11
quired for the submission of the report 
12
with respect to such device. 
13
‘‘(3) COVERAGE
AND
PAYMENT
AFTER
THE 
14
TRANSITIONAL
PERIOD.—The Secretary may con-
15
tinue to provide for coverage of and payment for a 
16
specified breakthrough device after the end of the 
17
transitional period of coverage and payment for 
18
breakthrough devices through the national coverage 
19
determination process if the Secretary determines 
20
that the specified breakthrough device— 
21
‘‘(A) improves the quality of care and pa-
22
tient outcomes; 
23
‘‘(B) improves the delivery of care; or 
24
05:09 Dec 13, 2019
H5333
21 
•HR 5333 IH
‘‘(C) reduces spending under this title 
1
without reducing the quality of care.’’. 
2
(b) STUDY OF LIMIT ON 510(k) BREAKTHROUGH 
3
DEVICES.— 
4
(1) STUDY.—The Secretary of Health and 
5
Human Services shall conduct a study on the effect 
6
of the limit under section 1899C(a)(2) of the Social 
7
Security Act, as added by subsection (a), on the 
8
number of devices cleared under section 510(k) of 
9
the Federal Food, Drug, and Cosmetic Act (21 
10
U.S.C. 360(k)) that are breakthrough devices for 
11
purposes of such section 1899C. 
12
(2) MATTERS
EXAMINED.—In conducting the 
13
study described in paragraph (1), the Secretary 
14
shall— 
15
(A) determine the number of medical de-
16
vices cleared under such section 510(k) during 
17
the 5-year period beginning on the date of the 
18
enactment of this Act; 
19
(B) determine the number of such devices 
20
that were not included as breakthrough devices 
21
for purposes of such section 1899C by reason 
22
of the limitation under subsection (a)(2) of such 
23
section; and 
24
20:39 Dec 15, 2019
H5333
22 
•HR 5333 IH
(C) examine the impact of such limitation 
1
on access to such devices for individuals entitled 
2
to benefits under part A or enrolled in part B 
3
of title XVIII of the Social Security Act (42 
4
U.S.C. 1395 et seq.) or both. 
5
(3) REPORT.—Not later than 6 years after the 
6
date of the enactment of this Act, the Secretary 
7
shall submit to Congress a report on the study con-
8
ducted under this subsection and shall include such 
9
recommendations for legislative or administrative 
10
changes as the Secretary determines to be appro-
11
priate. 
12
(c) CONFORMING AMENDMENTS.— 
13
(1) INPATIENT
PROSPECTIVE
PAYMENT
SYS-
14
TEM.—Section 1886(d)(5)(K) of the Social Security 
15
Act (42 U.S.C. 1395ww(d)(5)(K)) is amended by 
16
adding at the end the following new clause: 
17
‘‘(x) Effective for discharges occurring on 
18
or after October 1, 2019, in the case of a new 
19
medical service or technology that is a break-
20
through 
device 
(as 
defined 
in 
section 
21
1899C(a)), the additional payment established 
22
for such breakthrough device under this sub-
23
paragraph shall be made for the 3-year period 
24
applicable to such breakthrough device under 
25
05:09 Dec 13, 2019
H5333
23 
•HR 5333 IH
section 
1899C(d)(1). 
In 
determining 
the 
1
amount of the additional payment for a break-
2
through device under this subparagraph during 
3
such 3-year period, the Secretary shall apply 
4
section 412.88(b) of title 42, Code of Federal 
5
Regulations (or any successor regulation), as if 
6
the reference to ‘50 percent’ in such section 
7
were a reference to ‘80 percent’.’’. 
8
(2) OUTPATIENT PROSPECTIVE PAYMENT SYS-
9
TEM.—Section 1833(t)(6)(C) of such Act (42 U.S.C. 
10
1395l(t)(6)(C)) is amended by adding at the end the 
11
following new clause: 
12
‘‘(iii) SPECIAL
RULE
FOR
BREAK-
13
THROUGH
DEVICES.—Notwithstanding 
14
clause (i) or (ii), or any other provision of 
15
this paragraph to the contrary, in the case 
16
of a breakthrough device (as defined in 
17
section 1899C(a)) that is furnished on or 
18
after January 1, 2020, payment under this 
19
paragraph for such breakthrough device 
20
shall be made for the 3-year period appli-
21
cable to such breakthrough device under 
22
section 1899C(d)(2). The provisions of this 
23
clause shall also apply for purposes of 
24
05:09 Dec 13, 2019
H5333
24 
•HR 5333 IH
transitional pass-through payment under 
1
section 1833(i)(2)(D).’’. 
2
(3) COMPETITIVE BIDDING PROGRAM.—Section 
3
1847(a) of such Act (42 U.S.C. 1395w-3(a)) is 
4
amended— 
5
(A) in paragraph (2)(A)— 
6
(i) by striking ‘‘and excluding drugs’’ 
7
and inserting ‘‘excluding drugs’’; and 
8
(ii) by inserting before the period at 
9
the end the following: ‘‘and excluding 
10
breakthrough devices (as defined in section 
11
1899C(a))’’; and 
12
(B) in paragraph (7), by adding at the end 
13
the following new subparagraph: 
14
‘‘(C) BREAKTHROUGH DEVICES.—A break-
15
through device described in paragraph (2)(A) 
16
that is furnished during the transitional cov-
17
erage 
period 
(as 
defined 
in 
section 
18
1899C(b)(1)(B)) applicable to such device 
19
under section 1899C.’’. 
20
(d) EFFECTIVE DATE.—This section, and the amend-
21
ments made by this section, shall take effect on the date 
22
of the enactment of this Act and, unless otherwise speci-
23
fied in this section (or in an amendment made by this sec-
24
tion), shall apply to breakthrough devices (as defined in 
25
05:09 Dec 13, 2019
H5333
25 
•HR 5333 IH
section 1899C(a) of the Social Security Act, as added by 
1
subsection (a)), approved or cleared on or after July 1, 
2
2019, or, in the case of a specified breakthrough device 
3
(as defined in such section as so added), approved or 
4
cleared on or after December 1, 2018. 
5
Æ 
05:09 Dec 13, 2019
H5333
